Metformin, as a well-accepted oral drug for type 2 diabetes patients, could induce the augmented activation of AMPK in vitro and in vivo efficiently (46), so our work first found that Pdlim5, a component of muscle cytoskeleton that is related to many cardiovascular diseases (47), as a substrate of AMPK could be phosphorylated only by augmented activated AMPK, which induces the abolishment of the migratory machine in VSMCs in vitro and in vivo. This evidence concerns the gene PDLIM5 and type 2 diabetes mellitus.